Takeda Pharmaceutical (4502 JP): Recent Pipeline Blues Puts a Brake on Stock Recovery

Takeda Pharmaceutical (4502 JP): Bearish Tone Continues Despite New Drug Approvals

Taisho Pharma Seems the Best Suitor for Takeda’s Japan OTC Business

(Mostly Asia) M&A in 2018: What Was Hot, And What Was Not

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Hygeia Healthcare IPO (Part I): A Better Healthcare

Chart based progressive global trading strategies, Chart Partners

Thomas Schroeder

Chart based progressive global trading strategies

Chart Partners

Chart Partners objective is to discover medium-term cycle turns and profit opportunities before they unfold, within structural trends while preserving capital with clear degrees of risk. We have real return ideas. 

Markets are dynamic and trading systems must reflect this. It is crucial to determine underlying correlations and lead-lag relationships within global markets and the impact on linked instruments. Our weekly Chartonics product gives you short-term trading strategies that can be applied within the medium and longer term macro trends that are mapped out in our strategy updates. 

Our methodology fuses global market variables and isolates drivers in trends. We specialize in FX, index trade in NY and Asia with a focus on Asian stocks. 

Technical Analysis

Takeda Pharmaceutical / Technical Analysis

<a href="https://www.smartkarma.com/entities/takeda-pharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:11747:1" rel="noopener">Takeda Pharmaceutical (4502 JP)</a> demonstrates a bias to break below 3,580 pivot support into oversold territory ahead of staging a bounce cycle on the back of an RSI reading below 30. The macro bias remains bearish on bounces barring a breakout above trendline resistance.Macro cycle remains down barring a break above 4,200, representing the price and trendline break point that would turn the current down trend.Two trades are outlined. 1) A counter trend bounce play into short term weakness. 2) Short a bounce cycle in line with the current down trend.Sustained action below 3,580 will weigh on the macro cycle.

Takeda Pharmaceutical (4502 JP) demonstrates a bias to break below 3,580 pivot support into oversold territory ahead of staging a bounce cycle on the back of an RSI reading below 30. The macro bias remains bearish on bounces barring a breakout above trendline resistance.Macro cycle remains down barring a break above 4,200, representing the price and trendline break point that would turn the current down trend.Two trades are outlined. 1) A counter trend bounce play into short term weakness. 2) Short a bounce cycle in line with the current down trend.Sustained action below 3,580 will weigh on the macro cycle.

Takeda Pharmaceutical

Takeda Pharma Bear Press Below 3,580